Cyproheptadine Hydrochloride NDC 70752-101

NDC codes

FDA NDC Directory

Product NDC (as listed)70752-101Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70752-0101Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70752-101-12	70752010112	473 mL in 1 BOTTLE, GLASS (70752-101-12)Marketed from May 22, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cyproheptadine Hydrochloride
Generic name (nonproprietary): cyproheptadine hydrochloride
Active ingredients: Cyproheptadine hydrochloride — 2 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: QUAGEN PHARMACEUTICALS LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212423
Marketing start: May 22, 2019
Listing expires: Dec 31, 2026
Identifiers: Product ID 70752-101_4cf663f3-74cb-4b2c-b909-e6495d2ead78SPL ID 4cf663f3-74cb-4b2c-b909-e6495d2ead78SPL set ID d3ce21de-849a-47ab-8405-968d8de6f1e9RxCUI 866021UNII NJ82J0F8QC

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470752010112 followed by a unit qualifier and the quantity

Package 70752-0101-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 15, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212423

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212423
Product	Strength	Form · route	Labeler	Product NDC
Cyproheptadine Hydrochloride	Cyproheptadine hydrochloride 2 mg/5mL	SolutionOral	QUAGEN PHARMACEUTICALS LLC	70752-185
Cyproheptadine Hydrochloride	Cyproheptadine hydrochloride 2 mg/5mL	SolutionOral	Bryant Ranch Prepack	72162-2065
Cyproheptadine Hydrochloride	Cyproheptadine hydrochloride 2 mg/5mL	SolutionOral	Atlantic Biologicals Corp.	17856-1185